InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports P
Post# of 228
(Total Views: 88)
Posted On: 08/26/2024 5:10:00 PM
InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901
- A long-term preclinical study of Alzheimer’s Disease (“AD”) drug candidate INM-901 included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer’s Disease, and INM-901-treated Alzheimer’s Disease at two dosing levels
- The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments
- The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations
InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes from a long-term preclinical study of its Alzheimer’s Disease (“AD”) drug candidate, INM-901. These new findings confirm and expand upon results from a previous short-term pilot study (https://nnw.fm/ZcG5c ).
The long-term study, conducted over seven months, utilized the 5xFAD amyloidosis model, extending the dosing duration and increasing the sample size compared to the earlier three-month study. The study included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer’s Disease, and INM-901-treated Alzheimer’s Disease at two dosing levels. Given the progressive nature of the disease in this model, the groups in the long-term study exhibited more advanced AD than those in the short-term pilot.
The study assessed several behavioral criteria across the four groups. Cognitive function and memory were evaluated using the Novel Object Recognition Test, while general locomotor activity was measured through the Open Field Test. Anxiety-related behavior was gauged using the Elevated and Zero Maze Tests, spatial learning and memory were assessed with the Barnes Maze Test, and sound awareness was tested with the Acoustic Startle Test.
The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments. Significant improvements in specific behavioral criteria were noted compared to the placebo-treated AD groups, reinforcing and in some cases exceeding the outcomes of the short-term study.
Dr. Eric Hsu, Senior Vice President of Preclinical Research and Development at InMed, expressed optimism about the findings. “We are highly encouraged by the initial data from this long-term study, which supports the improvements in behavioral outcomes observed in our initial short-term preclinical Alzheimer’s proof-of-concept study. INM-901 continues to show potential by targeting multiple biological pathways associated with Alzheimer’s Disease, addressing the critical need for effective treatments,” Dr. Hsu added.
To better understand the mechanisms of action and the potential role of INM-901 in AD treatment, InMed is conducting further molecular analyses. These analyses will focus on receptor engagement (CB1/CB2 and PPAR), neuroinflammation (levels of various cytokines and inflammatory marker proteins), neurogenesis (markers for neuronal differentiation and function), and neuroprotection (evaluating stress responses and cellular growth/survival).
In addition to these analyses, the development of the chemistry, manufacturing, and controls (“CMC”) for both the drug substance and product formulation is ongoing. GLP studies are in the planning stages to support an IND submission.
Research and development activities to date have demonstrated that INM-901 targets several biological pathways associated with AD, exhibiting positive pharmacological characteristics. These include preferential signaling agonism for CB1/CB2 and impacts on PPAR signaling pathways, blood/brain barrier penetration with potential for oral administration, neuroprotective effects against amyloid-beta-induced cytotoxicity, and promotion of neurite outgrowth, indicating potential improvement in neuronal function.
The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations. InMed Pharmaceuticals continues to advance its research on INM-901, aiming to address the urgent need for effective Alzheimer’s treatments.
For more information, visit the company’s website at www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://nnw.fm/INM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- A long-term preclinical study of Alzheimer’s Disease (“AD”) drug candidate INM-901 included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer’s Disease, and INM-901-treated Alzheimer’s Disease at two dosing levels
- The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments
- The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations
InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes from a long-term preclinical study of its Alzheimer’s Disease (“AD”) drug candidate, INM-901. These new findings confirm and expand upon results from a previous short-term pilot study (https://nnw.fm/ZcG5c ).
The long-term study, conducted over seven months, utilized the 5xFAD amyloidosis model, extending the dosing duration and increasing the sample size compared to the earlier three-month study. The study included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer’s Disease, and INM-901-treated Alzheimer’s Disease at two dosing levels. Given the progressive nature of the disease in this model, the groups in the long-term study exhibited more advanced AD than those in the short-term pilot.
The study assessed several behavioral criteria across the four groups. Cognitive function and memory were evaluated using the Novel Object Recognition Test, while general locomotor activity was measured through the Open Field Test. Anxiety-related behavior was gauged using the Elevated and Zero Maze Tests, spatial learning and memory were assessed with the Barnes Maze Test, and sound awareness was tested with the Acoustic Startle Test.
The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments. Significant improvements in specific behavioral criteria were noted compared to the placebo-treated AD groups, reinforcing and in some cases exceeding the outcomes of the short-term study.
Dr. Eric Hsu, Senior Vice President of Preclinical Research and Development at InMed, expressed optimism about the findings. “We are highly encouraged by the initial data from this long-term study, which supports the improvements in behavioral outcomes observed in our initial short-term preclinical Alzheimer’s proof-of-concept study. INM-901 continues to show potential by targeting multiple biological pathways associated with Alzheimer’s Disease, addressing the critical need for effective treatments,” Dr. Hsu added.
To better understand the mechanisms of action and the potential role of INM-901 in AD treatment, InMed is conducting further molecular analyses. These analyses will focus on receptor engagement (CB1/CB2 and PPAR), neuroinflammation (levels of various cytokines and inflammatory marker proteins), neurogenesis (markers for neuronal differentiation and function), and neuroprotection (evaluating stress responses and cellular growth/survival).
In addition to these analyses, the development of the chemistry, manufacturing, and controls (“CMC”) for both the drug substance and product formulation is ongoing. GLP studies are in the planning stages to support an IND submission.
Research and development activities to date have demonstrated that INM-901 targets several biological pathways associated with AD, exhibiting positive pharmacological characteristics. These include preferential signaling agonism for CB1/CB2 and impacts on PPAR signaling pathways, blood/brain barrier penetration with potential for oral administration, neuroprotective effects against amyloid-beta-induced cytotoxicity, and promotion of neurite outgrowth, indicating potential improvement in neuronal function.
The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations. InMed Pharmaceuticals continues to advance its research on INM-901, aiming to address the urgent need for effective Alzheimer’s treatments.
For more information, visit the company’s website at www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://nnw.fm/INM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)